Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia.

摘要: In the past few years, number of effective treatment options for patients with chronic lymphocytic leukemia (CLL) has increased substantially. Purine analogs, bendamustine, monoclonal antibodies, and immunomodulatory drugs have shown higher response rates than previously achieved standard CLL treatments such as alkylating agents. However, a consequence is that tumor-cell killing may be accompanied by adverse secondary effects. One well-known rapid massive cell group metabolic disruptions collectively known tumor lysis syndrome (TLS). TLS can life threatening or fatal when unrecognized and/or untreated, cause delays in underlying disease. It important to aware patient risk factors, prophylactic measures, diagnostic criteria, TLS. This review discusses relevance provides guidelines diagnosis, prevention, being treated CLL.